Liminatus Pharma, Inc. Warrants (LIMNW) Stock Price
LIMNWStock
$0.05
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.47
LIMNW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-81.64%
Price vs S&P 500 (4W)-13.58%
VGM Score8.83
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LIMNWLiminatus Pharma, Inc. Warrants | — | — | F | $0.05 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Liminatus Pharma, Inc. Warrants
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company developing the GCC Vaccine, an immunotherapy in Phase II trials targeting colorectal, pancreatic, gastric, and esophageal cancers expressing Guanylyl Cyclase C. The vaccine is designed to stimulate immune responses against these gastrointestinal malignancies.